Contagion, February-March 2024 (Vol. 09, No. 1)

Clinicians review a patient case including diagnosis, treatment, and follow-up.

Clinicians discuss screening and treatment approaches for the disease.

There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.

The increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.

Here is a review of therapies for treating this bacterium.

Low-frequency resistant cells in bacterial isolates are challenging to detect and may contribute to unexplained treatment failure.

In the latest issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the continuous antibiotic trade-off of targeted vs broad spectrum therapies and cheap vs expensive options as they relate to UTI treatment.